Claims

1. Use of an a~~A~~gent in the manufacture of a medicament for the treatment of skin wounds or burns, wherein the agent is in a topical aseptic dosage form, which is used for reducing thermally-induced oedema and hyperemia, normalizing a neutrophil to lymphocyte ratio, stimulating formation of fibrous components in wound-induced scar tissue, and applied at least once daily until the wound is healed, and wherein the agent contains ~~in the form of a dosage form for topical use containing the~~ hexapeptide tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine at 0.02 - 0.5 weight % as the active ingredient, and at least one ~~with a~~ pharmaceutically acceptable excipient ~~/ pharmaceutically acceptable excipients making up the rest~~.

2. Agent according to claim 1, wherein the agent is a solution containing the hexapeptide tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine and a pharmaceutically acceptable excipient at the following ratio of the ingredients in weight %: hexapeptide tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine: 0.02 - 0.5 weight %, purified water up to 100 %.

3. Agent according to claim 1, wherein the agent is a gel containing the hexapeptide tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine and pharmaceutically acceptable excipients at the following ratio of the ingredients in weight %: hexapeptide tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine: 0.02 - 0.5 weight %, hydroxyethyl cellulose 2.5 - 3 %, potassium sorbate 2 - 3 %, purified water up to 100 %.